365 related articles for article (PubMed ID: 28119236)
1. Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
Liu Y; Gao F; Song W
Biomed Pharmacother; 2017 Apr; 88():342-348. PubMed ID: 28119236
[TBL] [Abstract][Full Text] [Related]
2. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
4. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
Chen Y; Li H; Chen D; Jiang X; Wang W; Li D; Shan H
Dig Dis Sci; 2022 Aug; 67(8):3806-3816. PubMed ID: 34383201
[TBL] [Abstract][Full Text] [Related]
6. Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carcinoma.
Tung JN; Cheng YW; Hsu CH; Liu TZ; Hsieh PY; Ting LL; Ko HL; Chang YJ; Chiou JF; Wu AT
Ann Surg Oncol; 2011 May; 18(5):1492-500. PubMed ID: 21181559
[TBL] [Abstract][Full Text] [Related]
7. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
8. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
9. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
11. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Jiao M; Nan KJ
Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
13. [The effect and mechanism of arsenic trioxide on hepatocellular carcinoma].
Liu LX; Zhu AL; Chen W; Guo HX; Wang XQ; Liu ZH; Zhang TD; Jiang HC; Wu M
Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(1):33-6. PubMed ID: 15774171
[TBL] [Abstract][Full Text] [Related]
14. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
15. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
[TBL] [Abstract][Full Text] [Related]
16. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
17. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans.
Kim Y; Jang M; Lim S; Won H; Yoon KS; Park JH; Kim HJ; Kim BH; Park WS; Ha J; Kim SS
Hepatology; 2011 Nov; 54(5):1661-78. PubMed ID: 21748762
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells.
Sadaf N; Kumar N; Ali M; Ali V; Bimal S; Haque R
Life Sci; 2018 Jul; 205():9-17. PubMed ID: 29738779
[TBL] [Abstract][Full Text] [Related]
19. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
[TBL] [Abstract][Full Text] [Related]
20. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J
Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
